S100 HSD are medicines for the treatment of conditions, which, because of their clinical use or other features, may generally only be prescribed by specialist medical practitioners affiliated with public or private hospitals with appropriate specialist facilities. As it is important that people living with HBV and HIV have access to high quality health care in primary care settings, the s100 HSD Program also provides for non- affiliated medical practitioners and nurse practitioners to be accredited to prescribe s100 HSD used in the treatment of HBV and HIV. With the introduction of new direct acting antiviral (DAA) treatments for Hepatitis C, it is now out of scope for inclusion as an s100 Highly Specialised Drug requiring accreditation and authorisation of community prescribers. In March 2016 the new DAAs for Hepatitis C were listed on the Pharmaceutical Benefits Scheme. The DAAs are now available on both the General Schedule (S85) and under the HSD Program (S100). Medical practitioners or nurse practitioners experienced in treating Hepatitis C, or in consultation with a  specialist experienced in treating Hepatitis C, can now prescribe DAAs under General Schedule (S85) and prescriptions can be dispensed through community pharmacies.

A non-affiliated medical practitioner or nurse practitioner may only prescribe HSDs for HBV and HIV if they are authorised as a community prescriber as outlined in this policy.